Combination therapies use two or more drugs as part of a single treatment regime for an increasing number of diseases, such as cancer. Combination treatments can deliver better outcomes for patients by targeting a disease via multiple pathways or at multiple levels.
Unfortunately, there are a number of barriers to making combination therapies more widely available. This includes the challenge that competing pharmaceutical businesses face in ensuring that discussions about potential combination therapies are compliant with competition law.
Aldwych Partners has been pleased to support Takeda, the international pharmaceutical company, to help develop a proposed solution that addresses these competition law constraints.
Of course, competition law is not the only challenge for combination treatments, and the proposed solution, set out in the Voluntary Arbitration Framework whitepaper, provides further detail on these issues and how they can be overcome through the proposed framework. A copy of the whitepaper is available by following this link to the Takeda website.